RA
ENTL

Royce & Associates’s Entellus Medical, Inc. Common Stock ENTL Stock Holding History

Royce & Associates’s Portfolio ENTL Stock Details ENTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-134,526
Closed -$3.28M – 1316
2017
Q4 		$3.28M Hold
134,526
– – 0.02% 721
2017
Q3 		$2.48M Hold
134,526
– – 0.02% 770
2017
Q2 		$2.23M Sell
134,526
-32,474
-19% -$452K 0.01% 818
2017
Q1 		$2.31M Buy
167,000
+124,000
+288% +$1.99M 0.02% 817
2016
Q4 		$816K Buy
+43,000
New +$825K 0.01% 970

Royce & Associates's ENTL Position: Q1 2018 in Review

Royce & Associates sold out of Entellus Medical, Inc. Common Stock (ENTL) in Q1 2018, closing a stake of 134,526 shares — an estimated $3.28M sold.

Royce & Associates first reported a position in ENTL in Q4 2016 and held it in 5 quarters. The position peaked at $3.28M in Q4 2017. 0 funds tracked by Wall St. Rank hold ENTL as of Q1 2018.

  • Royce & Associates reported no remaining Entellus Medical, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Royce & Associates sold 134,526 Entellus Medical, Inc. Common Stock shares in Q1 2018, an estimated $3.28M.
  • Royce & Associates first reported a position in Entellus Medical, Inc. Common Stock in Q4 2016 and held it in 5 quarters.
  • Royce & Associates's Entellus Medical, Inc. Common Stock position peaked at $3.28M in Q4 2017.
  • 0 funds tracked by Wall St. Rank held Entellus Medical, Inc. Common Stock as of Q1 2018.

Based on Royce & Associates's 13F filing for Q1 2018, filed 14 May 2018.